TP53 and cancer: In two CRC cancer cell lines (SW48 and HCT116), it was found that TP53 mutation can enhance the sensitivity of CRC cells to the ferroptosis inducer erastin, and P53 can also alter the distribution of DPP4 in the cell membrane with a transcription-independent manner (Figure 4) to inhibit CRC ferroptosis (100).